GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Initiator Pharma AS (OSTO:INIT) » Definitions » Debt-to-Asset

Initiator Pharma AS (OSTO:INIT) Debt-to-Asset : 0.00 (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Initiator Pharma AS Debt-to-Asset?

Initiator Pharma AS's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. Initiator Pharma AS's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was kr0.00 Mil. Initiator Pharma AS's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was kr23.59 Mil. Initiator Pharma AS's debt to asset for the quarter that ended in Dec. 2024 was 0.00.


Initiator Pharma AS Debt-to-Asset Historical Data

The historical data trend for Initiator Pharma AS's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Initiator Pharma AS Debt-to-Asset Chart

Initiator Pharma AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only - 0.25 0.26 0.52 -

Initiator Pharma AS Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.52 - - - -

Competitive Comparison of Initiator Pharma AS's Debt-to-Asset

For the Biotechnology subindustry, Initiator Pharma AS's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Initiator Pharma AS's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Initiator Pharma AS's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Initiator Pharma AS's Debt-to-Asset falls into.


;
;

Initiator Pharma AS Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Initiator Pharma AS's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Initiator Pharma AS's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Initiator Pharma AS  (OSTO:INIT) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Initiator Pharma AS Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Initiator Pharma AS's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Initiator Pharma AS Business Description

Traded in Other Exchanges
N/A
Address
Co/ COBIS, Ole Maaloesvej 3, Copenhagen, DNK, 2200
Initiator Pharma AS is a research and development company engaged in the pharmaceutical development of drugs to be used for erectile dysfunction, depression, and pain. It Research is focused in the area of monoamine reuptake inhibitors.

Initiator Pharma AS Headlines

No Headlines